VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declines

Journal:

Science Translational Medicine

Published:

2026-05-06

DOI:

10.1126/scitranslmed.adr4509

Affiliations:

21

Authors:

32

Go to article

Institutions	Authors	Share
NIH National Institute of Allergy and Infectious Diseases (NIAID), United States of America (USA)	4.000000	0.13
NIH NIAID Vaccine Research Center (VRC), United States of America (USA)	4.000000	0.13
Harvard University, United States of America (USA)	2.000000	0.06
FHI 360, United States of America (USA)	2.000000	0.06
NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), United States of America (USA)	2.000000	0.06
University of Colorado Anschutz Medical Campus (CU Anschutz), United States of America (USA)	2.000000	0.06
LabCorp, United States of America (USA)	2.000000	0.06
Botswana Harvard AIDS Institute Partnership (BHP), Botswana	2.000000	0.06
Indiana University (IU), United States of America (USA)	1.000000	0.03
University of California, San Diego (UC San Diego), United States of America (USA)	1.000000	0.03
Frontier Science Foundation, United States of America (USA)	1.000000	0.03
Stellenbosch University (SU), South Africa	1.000000	0.03
University of California, Los Angeles (UCLA), United States of America (USA)	1.000000	0.03
Johns Hopkins Research Project - Malawi, Malawi	1.000000	0.03
Kamuzu University of Health Sciences (KUHeS), Malawi	1.000000	0.03
UNC Project-Malawi (UNC Project), Malawi	1.000000	0.03
University of Zimbabwe (UZ), Zimbabwe	1.000000	0.03
Hospital Federal dos Servidores do Estado (HFSE), Brazil	1.000000	0.03
Hospital Geral de Nova Iguaçu (HGNI), Brazil	1.000000	0.03
Johns Hopkins University (JHU), United States of America (USA)	1.000000	0.03

Interested in Clinical Sciences?